United Kingdom - English - myHealthbox

actavis group ptc ehf - codeine phosphate hemihydrate/paracetamol - film-coated tablets - 30/500mg - codeine, combinations excl. psycholeptics - for the relief of moderate to severe pain in adults and children above 12 years. codeine is indicated in patients older than 12 years of age for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen (alone).

United Kingdom - English - myHealthbox

actavis group ptc ehf - codeine phosphate hemihydrate/paracetamol - film-coated tablets - 60/1000mg - codeine, combinations excl. psycholeptics - for the relief of moderate to severe pain in adults and adolescents 16 years and older. codeine is indicated in patients 16 years and older for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen

United Kingdom - English - myHealthbox

actavis group ptc ehf - gliclazide - modified-release tablet - 30mg - a10bb09 - non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose

United Kingdom - English - myHealthbox

actavis group ptc ehf - gliclazide - modified-release tablet - 60mg - blood glucose lowering drugs, excl. insulins: sulfonylureas - non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - dutasteride - capsule, soft - 0.5 milligram(s) - testosterone-5-alpha reductase inhibitors; dutasteride - drugs used in benign prostatic hypertrophy - testosterone-5-alpha-reductase inhibitors - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dch auriga (malaysia) sdn. bhd. - ezetimibe -

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - gliclazide - modified-release tablet - 30 milligram(s) - sulfonamides, urea derivatives; gliclazide - blood glucose lowering drugs, excl. insulins: sulfonylureas - non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - isosorbide mononitrate (unii: lx1oh63030) (isosorbide mononitrate - unii:lx1oh63030) - isosorbide mononitrate 10 mg - isosorbide mononitrate tablets, usp are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. the onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. isosorbide mononitrate is contraindicated in patients who are allergic to it. do not use isosorbide mononitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia. do not use isosorbide mononitrate in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid - antithrombotic agents: platelet aggregation inhibitors excl. heparin - it is used for: secondary prevention of myocardial infarction, prevention of cardiovascular morbidity in patients suffering from stable angina pectoris, history of unstable angina pectoris, except during the acute phase, prevention of graft occlusion after coronary artery bypass grafting (cabg), coronary angioplasty, except during the acute phase, secondary prevention of transient ischaemic attacks (tia) and ischaemic cerebrovascular accidents (cva), provided intracerebral haemorrhages have been ruled out.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - oxybutynin chloride tablets usp are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). oxybutynin chloride is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. oxybutynin chloride is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.